#United States #Los Angeles #DJS Law Group #Soleno Therapeutics #SLNO

Soleno Therapeutics Class Action Overview

In an ongoing legal battle, Soleno Therapeutics, Inc. (NASDAQ: SLNO) finds itself facing a class action lawsuit for alleged violations concerning securities laws. The lawsuit has been initiated by the DJS Law Group, which reminds potential claimants of the pressing deadlines and the importance of taking action.

Background of the Case

The claims stem from a class period beginning on March 26, 2025, and concluding on November 4, 2025. During this timeframe, investors who purchased shares of Soleno Therapeutics may have been misled by the company's communications, which allegedly contained false and misleading statements.

At the center of the allegations is the company's Phase 3 clinical trial of diazoxide choline extended-release tablets (DCCR). According to the complaint, the trial raised significant safety concerns regarding the drug candidate, which the company subsequently downplayed. Results indicated that DCCR was losing its commercial viability, a situation that contradicted Soleno's public messaging. As a result, investors are concerned that Soleno's actions and statements were not just misleading, but also materially false.

The DJS Law Group is actively seeking shareholders who might have suffered losses due to these events. Newly affected individuals are encouraged to reach out and discuss their options; appointment as a lead plaintiff is not necessary for participating in any financial recovery.

Why Pursue This Case?

Investors participating in this class action can potentially recover damages resulting from their losses. It's essential for shareholders, especially those with substantial stakes in Soleno, to explore their rights and legal avenues.

The DJS Law Group prides itself on robust advocacy for its clients, specializing in securities class actions, corporate governance litigation, and both domestic and international appraisal processes. They represent many of the world's leading hedge funds and asset managers, reflecting their expertise in handling complex litigation that can significantly impact investors.

DJS Law Group aims to ensure investor returns through careful guidance and aggressive representation in this legal undertaking.

Call to Action

Affected shareholders must act swiftly, as the deadline for joining this class action is May 5, 2026. If you purchased shares of Soleno Therapeutics during the specified class period and believe you have incurred a loss due to their misleading conduct, contacting the DJS Law Group can be a critical step toward seeking justice.

The law group reminds potential participants that this press release may be seen as attorney advertising in some jurisdictions, emphasizing the need for informed engagement. For those interested, further information can be obtained by contacting the legal team directly as they navigate these proceedings, protecting investor rights and aiming to recover losses.

Contact Information

For additional queries or to take part in the class action, investors should reach out to:
David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: [email protected]

In conclusion, the legal landscape for Soleno Therapeutics remains fraught with complexities. Stakeholders should remain vigilant, as the outcome of this lawsuit could have substantial implications for both the company and its investors.